

Dermatology Matters Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 June 2025

Dermatology Matters Limited

CONTENTS

	Page
Directors' Responsibilities Statement	3
Statement of Financial Position	4 - 5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 11

Dermatology Matters Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Cal Condon
Director

Patricia McCarthy Condon
Director

5 March 2026

Dermatology Matters Limited
STATEMENT OF FINANCIAL POSITION

as at 30 June 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Property, plant and equipment	7	<u>344,244</u>	<u>418,404</u>
Current Assets			
Debtors	8	1,407,082	1,140,186
Cash and cash equivalents		<u>431,387</u>	<u>509,544</u>
		<u>1,838,469</u>	<u>1,649,730</u>
Creditors: amounts falling due within one year	9	<u>(359,944)</u>	<u>(357,010)</u>
Net Current Assets		<u>1,478,525</u>	<u>1,292,720</u>
Total Assets less Current Liabilities		<u>1,822,769</u>	<u>1,711,124</u>
Creditors: amounts falling due after more than one year	10	<u>(22,803)</u>	<u>(73,651)</u>
Net Assets		<u><u>1,799,966</u></u>	<u><u>1,637,473</u></u>
Capital and Reserves			
Called up share capital presented as equity	12	100	100
Retained earnings		<u>1,799,866</u>	<u>1,637,373</u>
Equity attributable to owners of the company		<u><u>1,799,966</u></u>	<u><u>1,637,473</u></u>

Dermatology Matters Limited

STATEMENT OF FINANCIAL POSITION

as at 30 June 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Dermatology Matters Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 5 March 2026 and signed on its behalf by:

Cal Condon
Director

Patricia McCarthy Condon
Director

Dermatology Matters Limited
STATEMENT OF CHANGES IN EQUITY

as at 30 June 2025

	Called up share capital €	Retained earnings €	Total €
At 1 July 2023	100	1,301,609	1,301,709
Profit for the financial year	-	485,764	485,764
Payment of dividends	-	(150,000)	(150,000)
At 30 June 2024	100	1,637,373	1,637,473
Profit for the financial year	-	282,493	282,493
Payment of dividends	-	(120,000)	(120,000)
At 30 June 2025	100	1,799,866	1,799,966

Dermatology Matters Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

1. General Information

Dermatology Matters Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 558054. The registered office of the company is Suite 5, Blackrock Clinic, Blackrock, Co.Dublin, Ireland which is also the principal place of business of the company. The principal activity of the company is the provision of medical and cosmetic skin care.

Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 June 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods and services supplied by the company.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Plant and machinery	-	12.5%/ 25% Straight line/Life of Lease
Fixtures, fittings and equipment	-	12.5%/ 25% Straight line
Motor vehicles	-	25% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Leasing and hire purchases

Property, plant and equipment held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Statement of Financial Position at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Income Statement.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Dermatology Matters Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. No defined benefit pension schemes are in place.

Pension contributions of €6,800 were payable at 30/06/2025.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Dividends

It is anticipated that the company will pay dividends to its shareholders every year. Thereafter, to the extent that the board declare dividends these shall be declared on an irregular dividend policy basis and paid on all appropriate classes of shares.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Turnover

The whole of the company's turnover is attributable to its market in the Republic of Ireland and is derived from the principal activity of the provision of medical and cosmetic skin care.

4. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of property, plant and equipment	88,813	89,297
(Profit)/loss on disposal of property, plant and equipment	-	6,288
Loss on foreign currencies	390	166
	<u> </u>	<u> </u>
5. Interest payable and similar expenses	2025	2024
	€	€
Interest	7,845	13,152
	<u> </u>	<u> </u>

Dermatology Matters Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 June 2025

6. Employees

The average monthly number of employees, including directors, during the financial year was 18, (2024 - 18).

	2025 Number	2024 Number
Administration	6	6
Directors	2	2
Nursing Staff	10	10
	<u>18</u>	<u>18</u>

7. Property, plant and equipment

	Plant and machinery €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost				
At 1 July 2024	602,315	155,616	84,997	842,928
Additions	-	14,653	-	14,653
At 30 June 2025	<u>602,315</u>	<u>170,269</u>	<u>84,997</u>	<u>857,581</u>
Depreciation				
At 1 July 2024	337,398	70,127	16,999	424,524
Charge for the financial year	56,765	15,049	16,999	88,813
At 30 June 2025	<u>394,163</u>	<u>85,176</u>	<u>33,998</u>	<u>513,337</u>
Net book value				
At 30 June 2025	<u>208,152</u>	<u>85,093</u>	<u>50,999</u>	<u>344,244</u>
At 30 June 2024	<u>264,917</u>	<u>85,489</u>	<u>67,998</u>	<u>418,404</u>

7.1. Property, plant and equipment continued

Included above are assets held under finance leases or hire purchase contracts as follows:

	2025 Net book value €	Depreciation charge €	2024 Net book value €	Depreciation charge €
Plant and machinery	<u>159,621</u>	<u>43,742</u>	<u>199,124</u>	<u>39,503</u>

8. Debtors

	2025 €	2024 €
Amounts owed by group undertakings	1,198,028	1,089,356
Directors Loan	103,872	-
Directors' current accounts	-	(47,452)
Taxation	105,182	98,282
	<u>1,407,082</u>	<u>1,140,186</u>

Dermatology Matters Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

9. Creditors			2025	2024
Amounts falling due within one year			€	€
Net obligations under finance leases and hire purchase contracts			50,846	83,722
Trade creditors			67,353	8,996
Amounts owed to group undertakings			103,423	103,073
Taxation			116,292	132,539
Other creditors			13,147	19,624
Pension accrual			6,800	6,973
Accruals			2,083	2,083
			359,944	357,010
10. Creditors			2025	2024
Amounts falling due after more than one year			€	€
Finance leases and hire purchase contracts			22,803	73,651
Net obligations under finance leases and hire purchase contracts				
Repayable within one year			50,846	83,722
Repayable between one and five years			22,803	73,651
			73,649	157,373
11. Taxation			2025	2024
			€	€
Debtors:				
Withholding tax			105,182	98,282
Creditors:				
VAT			2,174	2,424
Corporation tax			53,435	66,864
PAYE			60,683	63,251
			116,292	132,539
12. Share capital			2025	2024
			€	€
Description	Number of shares	Value of units		
Authorised				
Ordinary shares	100,000	€1.00 each	100,000	100,000
Allotted, called up and fully paid				
Ordinary shares	100	€1.00 each	100	100

Dermatology Matters Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

No director or the secretary had an interest in the share capital of the company at any time during the period. The directors' and the secretary's interests in the share capital of other group companies are as follows:

Name	Company	Class of Shares	Number Held	
			At 30/06/25	01/07/24
Holdings in Parent Company				
Cal Condon	Condon Medical Limited	Ordinary shares of €1 each	379	379
Patricia McCarthy Condon	Condon Medical Limited	Ordinary shares of €1 each	187	187
			=	=

13. Income Statement

	2025 €	2024 €
At 1 July 2024	1,637,373	1,301,609
Profit for the financial year	282,493	485,764
Payment of dividends	(120,000)	(150,000)
	=	=
At 30 June 2025	1,799,866	1,637,373

14. Capital commitments

The company had no material capital commitments at the financial year-ended 30 June 2025.

15. Directors' remuneration

	2025 €	2024 €
Remuneration	254,000	254,000
Pension contributions	370,000	-
	=	=
	624,000	254,000

16. Related party transactions

The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.

Dermatology Matters Limited and Dermatology Products Limited share common control.

17. Parent company

The company regards Condon Medical Limited as its parent company. Condon Medical Limited, Suite 6 Blackrock Clinic, Blackrock, Co Dublin. The principal activity of the holding company is the holding and managing of investments.

18. Events After the End of the Reporting Period

There have been no significant events affecting the company since the financial year-end.

19. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 5 March 2026.